Interestingly, these findings mirror those from a pancreatic cancer model in which at 12 weeks after KRAS mutant activation, KrasG12D mice showed more extensive pancreatic intraepithelial neoplasias (PanINs) compared to KrasG12C mice. Here, KRAS is linked to pancreatic neoplasm.